Eli Lilly and Company (NYSE:LLY) Trading Down 1.4% – Here’s Why

Eli Lilly and Company (NYSE:LLY)’s stock price traded down 1.4% during mid-day trading on Tuesday . The stock traded as low as $1,071.60 and last traded at $1,064.5180. 2,689,714 shares were traded during mid-day trading, a decline of 13% from the average session volume of 3,100,566 shares. The stock had previously closed at $1,079.9610.

Trending Headlines about Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Eli Lilly expanded its pipeline with a $1.9 billion partnership with Ascidian Therapeutics focused on kidney disease treatments, reinforcing management’s strategy of using obesity cash flow to fund acquisitions and diversify beyond GLP-1 drugs. Eli Lilly, Ascidian Sign $1.9 Billion Kidney-Disease Treatment Deal
• Positive Sentiment: Lilly reported encouraging clinical updates for its obesity and immunology pipeline, including progress in the TRIUMPH-1 retatrutide study and a pediatric ulcerative colitis trial for mirikizumab, both of which support longer-term growth expectations. Lilly’s TRIUMPH-1 Retatrutide Trial Reaches Key Milestone in Obesity Drug Race Lilly’s Pediatric Ulcerative Colitis Trial Marks Key Step for Mirikizumab Growth
• Positive Sentiment: Coverage news also remained favorable, with CVS Caremark and other major pharmacy benefit managers broadening access to Lilly’s obesity portfolio, which should improve prescription volume for Zepbound and Foundayo. Eli Lilly Wins Back CVS Health, Reverting Novo’s Advantage

Analyst Upgrades and Downgrades

Several research firms have issued reports on LLY. UBS Group restated a “buy” rating on shares of Eli Lilly and Company in a research note on Wednesday, March 18th. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating and set a $1,285.00 target price on shares of Eli Lilly and Company in a research note on Friday, March 6th. Daiwa Securities Group boosted their target price on Eli Lilly and Company from $1,230.00 to $1,250.00 and gave the stock a “buy” rating in a report on Wednesday, February 18th. The Goldman Sachs Group reaffirmed a “buy” rating and set a $1,283.00 price target on shares of Eli Lilly and Company in a report on Friday, May 22nd. Finally, Wells Fargo & Company lifted their price objective on shares of Eli Lilly and Company from $1,200.00 to $1,280.00 and gave the stock an “overweight” rating in a research report on Thursday, February 5th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $1,227.00.

Eli Lilly and Company Trading Up 1.6%

The business has a fifty day moving average price of $965.78 and a 200-day moving average price of $1,011.48. The company has a quick ratio of 1.10, a current ratio of 1.50 and a debt-to-equity ratio of 1.26. The company has a market cap of $1.02 trillion, a P/E ratio of 38.41, a PEG ratio of 1.16 and a beta of 0.53.

Eli Lilly and Company (NYSE:LLY) last announced its earnings results on Thursday, April 30th. The company reported $8.55 earnings per share for the quarter, topping analysts’ consensus estimates of $6.97 by $1.58. The company had revenue of $19.80 billion for the quarter, compared to analyst estimates of $17.82 billion. Eli Lilly and Company had a return on equity of 105.77% and a net margin of 34.98%.The firm’s quarterly revenue was up 55.5% compared to the same quarter last year. During the same quarter last year, the company earned $3.34 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. On average, analysts forecast that Eli Lilly and Company will post 35.8 earnings per share for the current year.

Eli Lilly and Company Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, June 10th. Shareholders of record on Friday, May 15th will be given a dividend of $1.73 per share. The ex-dividend date is Friday, May 15th. This represents a $6.92 annualized dividend and a yield of 0.6%. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 24.58%.

Institutional Investors Weigh In On Eli Lilly and Company

A number of institutional investors have recently modified their holdings of the business. Cidel Asset Management Inc. raised its position in Eli Lilly and Company by 26.5% in the third quarter. Cidel Asset Management Inc. now owns 26,726 shares of the company’s stock valued at $20,392,000 after purchasing an additional 5,591 shares during the last quarter. Spire Wealth Management grew its holdings in shares of Eli Lilly and Company by 2.2% during the fourth quarter. Spire Wealth Management now owns 27,719 shares of the company’s stock worth $29,789,000 after purchasing an additional 592 shares during the last quarter. Coldstream Capital Management Inc. grew its holdings in shares of Eli Lilly and Company by 25.6% during the third quarter. Coldstream Capital Management Inc. now owns 42,418 shares of the company’s stock worth $32,365,000 after purchasing an additional 8,659 shares during the last quarter. Farther Finance Advisors LLC increased its stake in shares of Eli Lilly and Company by 30.8% in the fourth quarter. Farther Finance Advisors LLC now owns 31,145 shares of the company’s stock valued at $33,471,000 after buying an additional 7,338 shares during the period. Finally, Teachers Retirement System of The State of Kentucky raised its holdings in Eli Lilly and Company by 3.5% in the 3rd quarter. Teachers Retirement System of The State of Kentucky now owns 165,165 shares of the company’s stock valued at $126,022,000 after buying an additional 5,595 shares during the last quarter. Institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.